SB 913

Drug Profile

SB 913

Alternative Names: SB-913

Latest Information Update: 07 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sangamo Therapeutics
  • Class Gene therapies; Zinc finger DNA binding proteins
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis II
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Mucopolysaccharidosis II

Most Recent Events

  • 07 Jun 2018 UK MHRA approves clinical trial application (CTA) for SB 913 in Mucopolysaccharidosis II
  • 04 Jun 2018 Sangamo Therapeutics intends to expand the phase I/II trial for Mucopolysaccharidosis II in United Kingdom in late 2018
  • 04 Apr 2018 Pharmacodynamics data from a preclinical trial in mucopolysaccharidosis II released by Sangamo Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top